We invite you into live conversations about the future of inhaled anesthetics with thought leaders, scientists, researchers, and industry professionals. These sessions focus on the science, the clinical context, and the business implications of advancing new agents in a field that has seen little progress in more than fifty years.
Beyond Intraoperative Hypotension: A look at hypotension, anesthetic tradeoffs, and future possibilities. In this presentation, Dr. Joseph Antognini, CSO of Expanesthetics, explores how anesthetic choices influence intraoperative hypotension and patient outcomes, and the emerging possibilities for more hemodynamically stable agents.
Expanesthetics is based on groundbreaking science at the forefront of anesthetic research. Dr. Robert Brosnan, the inventor behind our technology, is the student and academic heir of Ted Eger, industry luminary and contemporary of other 20th century leaders such as Ross Terrell. Dr. Brosnan's discovery gives Expanesthetics a path for developing new inhaled general anesthetics with fewer side effects and new beneficial effects.
Our foundational research has yielded multiple proof-of-concept candidates with compelling characteristics like cardiovascular stability and potential for native analgesia.
Over 100 anesthesiologists have invested in Expanesthetics, and the company is run by an experienced team of business, clinical, and research leaders. These include luminaries in the field of anesthesia, people who have managed billion-dollar enterprises, and leaders in both public and private companies.
"As an acute pain and regional anesthesiologist, my practice focuses on advancing clinical anesthesia. I joined the Expanesthetics team as a shareholder because I see the potential for the technology to create incredibly positive change not only for my practice, but for the practice of anesthesia around the world."
Chauncey T. Jones, MD
Anesthesiologist and Business Owner
Houston, TX
